Navigation Links
Infinata’s BioPharm Insight Signs 200th Media Partner, Inaugurates Advertising Program

Norwood, MA (PRWEB) February 14, 2013

Infinata’s BioPharm Insight™ announced it signed its 200th media partner and unveiled an advertising program designed to help partners increase attendance at their events. BioPharm Insight offers the global biopharmaceutical community a unique combination of business intelligence, market analytics, key industry contacts, and award-winning independent investigative journalism.

Infinata partners with businesses and organizations within all biopharma and wealth sectors to promote industry-changing events such as conferences and symposia. Media partners include:

  •     Biotechnology Industry Organization (BIO)
  •     Drug Information Association (DIA)
  •     The Conference Forum
  •     EBD Group
  •     SMi Group
  •     HealthNetwork Communications
  •     Worldwide Business Research (WBR)
  •     Partnerships in Clinical Trials
  •     The Financial Times
  •     ExL Pharma
BioPharm Insight Inaugurates Advertising Program

Industry professionals rely on BioPharm Insight’s newsletter program to stay ahead of their competition with updates on proprietary forward-looking intelligence, clinical trial news, and upcoming industry conferences. BioPharm Insight has created a new opportunity to get in front of these influential executives with a completely redesigned newsletter providing optimal space for companies to promote their solutions.

Jim Davis, Infinata’s Global Head of Sales for its BioPharm Suite, said, “Media partners and advertisers rely on BioPharm Insight to develop awareness and reach the most influential decision makers in the biopharma industry.”

To learn more about becoming a BioPharm Insight Media Partner or to take advantage of the new Advertising Program, please contact Holly Burke at hburke(at)infinata(dot)com or 781-619-0131.

Learn how BioPharm Insight can help you find new business opportunities by starting a free trial today.

About BioPharm Insight
BioPharm Insight is the definitive guide to the global biopharma community. BioPharm Insight provides subscribers with an information edge by combining the most comprehensive real-time database of companies, drugs, contacts, M&A and licensing deals, forecasts and clinical trial data with proprietary forward-looking intelligence uncovered by an independent team of investigative journalists months or even years before it breaks in mainstream media. To learn more, visit Follow BioPharm Insight on LinkedIn and Twitter.

About Infinata, Inc.
Infinata provides personalized technology solutions to turn information into insight. Services include a comprehensive BioPharm Solutions Suite, unique Wealth Prospecting tools and innovative Custom Data Services. Infinata is a part of Mergermarket, a Financial Times Group company and a division of Pearson plc. To learn more, visit

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Infinata’s BioPharm Insight™ Achieves Record Growth in 2012
2. Keryx Biopharmaceuticals to Present at the 15th Annual BIO CEO & Investor Conference Presentation Scheduled for Monday, February 11th at 2:30 PM ET
3. Array BioPharma Reports Financial Results For The Second Quarter Of Fiscal 2013
4. Infinata's BioPharm Clinical™ to Present Session on Improving Investigator Selection at CHI’s Summit for Clinical Operations (SCOPE) on February 6 in Miami, FL
5. Sutro Biopharma Appoints Edward C. Albini as Chief Financial Officer
6. Array BioPharma To Report Financial Results For The Second Quarter Of Fiscal 2013 On February 4, 2013
7. BioPharm Systems to Host Webinar on an Add-On Solution for Oracle Clinical
8. BioPharm Systems to Host Webinar on Self-service Account Management for Oracle Clinical, Remote Data Capture, and Thesaurus Management System
9. Array BioPharma Provides Updates On Clinical Data At The 2012 American Society Of Hematology Meeting
10. TransCelerate BioPharma Inc. Appoints Dalvir Gill as Chief Executive Officer
11. Array BioPharma Announces Exercise And Closing Of Underwriters Over-Allotment Option
Post Your Comments:
(Date:6/27/2016)... 27, 2016  Global demand for enzymes is ... 2020 to $7.2 billion.  This market includes enzymes ... products, biofuel production, animal feed, and other markets) ... biocatalysts). Food and beverages will remain the largest ... consumption of products containing enzymes in developing regions.  ...
(Date:6/27/2016)... ... June 27, 2016 , ... Cancer ... what they believe could be a new and helpful biomarker for malignant pleural ... Click here to read it now. , Biomarkers are components in the ...
(Date:6/27/2016)... , ... June 27, 2016 , ... ... for Amgen, will join the faculty of the University of North Carolina ... professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on the ...
(Date:6/24/2016)... on a range of subjects including policies, debt and investment ... Speaking at a lecture to the Canadian Economics ... the country,s inflation target, which is set by both the ... "In certain areas there needs to be frequent ... not sit down and address strategy together?" He ...
Breaking Biology Technology:
(Date:5/16/2016)... 16, 2016   EyeLock LLC , a market ... opening of an IoT Center of Excellence in ... the development of embedded iris biometric applications. ... convenience and security with unmatched biometric accuracy, making it ... from DNA. EyeLock,s platform uses video technology to deliver ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
(Date:4/26/2016)... India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a product ... and Onegini today announced a partnership to integrate ... solutions.      (Logo: ... to provide their customers enhanced security to access ...
Breaking Biology News(10 mins):